Trop-2 is a calcium signal transducer that is associated with transformed cell growth in experimental systems. However, its role in human cancer remains essentially unknown. In this study, we profiled Trop-2 expression in normal human tissues at the mRNA and protein levels. We then systematically compared Trop-2 mRNA and protein levels in tumours with their tissues of origin. We find that Trop-2 expression is invariably upregulated in tumours, regardless of baseline expression in normal tissues, which suggests a corresponding selective advantage. Thus, we investigated the outcome of Trop-2 upregulation on tumour growth. Overexpression of wild-type Trop-2 was shown to be necessary and sufficient to drive cancer growth in a widely invariant manner across cell type and species. Upregulation of Trop-2 was shown to quantitatively stimulate tumour growth, as proportional to expression levels in vivo, and tumour cell growth was abrogated by somatic knockdown of Trop-2 expression. On the other hand, we found no evidence of tumour-associated TROP2 mutations, nor of TROP2 induction of oncogenic transformation per se. Our data support a model where above-baseline expression of wild-type Trop-2 is a key driver of human cancer growth.
INTRODUCTION
We cloned the TROP2/TACSTD2 gene 1 as encoding a transmembrane Ca þ þ -signal transducer, 2 shared by trophoblast cells, normal multistratified epithelia and carcinomas. Trop-2 has since been shown to have a role in tumour growth in experimental models. 3 --7 Trop-2 was shown to be a marker for neoplastic and normal prostate stem cells. 3, 8 The expression of Trop-2 has been associated with biological aggressiveness and poor prognosis of pancreatic, 9 gastric, 10 oral, 11 colorectal 12, 13 and ovarian 14 cancers, suggesting that it has a role in tumour progression. Trop-2 has also been proposed as a target for anticancer immunotherapy, 15 and anti-Trop-2 monoclonal antibodies (mAbs) have been shown to kill uterine serous papillar carcinoma cells via Ab-dependent cell-mediated cytotoxicity in vitro. 16 However, Trop-2 has also been detected in normal tissues, 17 --21 which has raised issues both to its function in cancer and to a possible toxicity of Trop-2-targeting anticancer immunotherapy. 22 Here, we defined the Trop-2 expression profile in normal human tissues at the mRNA and protein levels. We then systematically compared Trop-2 expression in tumours with that in their normal tissues of origin, in bulk, large-sized data sets, and in series of tissue pairs of normal and transformed cells from individual patients. Our findings show that Trop-2 is expressed in a number of normal tissues, sometimes at high levels. However, these expression levels invariably increase in the corresponding tumours. Overexpression of Trop-2 and somatic knockdown studies demonstrated that Trop-2 upregulation is both necessary and sufficient for human cancer growth. We found no evidence of activating mutations in TROP2 genes from tumours, nor of oncogenic transformation of primary cells. Instead, we show that the increase in cancer growth in experimental models in vivo is directly proportional to Trop-2 expression levels. Thus, we propose a model whereby above-baseline expression of wild-type Trop-2 has a key driving role in the growth of most human cancers.
RESULTS

Trop-2 is expressed in normal human tissues
A comprehensive scenario of Trop-2 expression in normal tissues is still missing. Hence, we systematically explored the expression profile of the TROP2 gene (Figures 1 and 2 ; Table 1 ). DNA microarray and real-time PCR analyses showed expression of TROP2 mRNA in breast, cervix, endometrium, oesophagus, fallopian tubes, kidney, multistratified epithelia, 17 pancreas, placenta, prostate, respiratory tract, salivary glands, seminal vesicles, stomach, tonsils, thymus and vagina (Figures 1a and b) . cDNA sequencing-based tools, for example, serial analysis of gene expression (SAGE), 23 supported and extended these results 24 ( Figure 2a) , showing TROP2 transcripts in normal tissues from lung, breast, stomach, kidney, colorectum, prostate and skin. Expression profiling by filter hybridization (Figure 2c ; Table 1 , top) supported these findings, with the demonstration of high levels of TROP2 mRNA in breast, prostate and endometrium, intermediate expression in lung, stomach, kidney and pancreas, and low/nil expression in ovary.
We then performed extensive immunohistochemistry (IHC) analyses to define the expression patterns of the Trop-2 protein in normal tissues ( Figure 3 ; Supplementary Figure 1 ; Table 1,  bottom; Table 2 ). IHC was performed with anti-Trop-2 murine mAb and goat polyclonal Ab (pAb). Anti-Trop-2 pAb (AF650; R&D Systems, Minneapolis, MN, USA) is obtained from goats immu-nized with mammalian cell-derived, recombinant Trop-2 extracellular domains, that is, with mature, glycosylated molecules. This leads to prevailing reactivity against cell surface molecules, and reveals major Trop-2 accumulation at cell --cell contact sites (Figure 3a) . The anti-Trop-2 murine mAb shows broader reactivity towards intracellular structures (Figure 3b ). To clarify the nature of the intracellular deposits, confocal microscopy immunofluorescence analysis of Trop-2 subcellular localization was performed. Z-stack analysis of TROP2 transfectants confirmed presence in saccular deposits and in the Golgi (Figure 4a ).
As the resolution of optical microscopy does not allow accurate identification of intracellular structures, Trop-2-expressing cells were analysed by electron microscopy (EM) with the anti-Trop-2 mAb (Figures 4b and c) . In addition to the cell membrane, immunogold and immunoperoxidase EM demonstrated Trop-2 in endoplasmic reticulum, Golgi, post-Golgi compartments and vesicles, that is, sites of post-translational glycosylation and transport to the membrane.
Both anti-Trop-2 mAb and pAb revealed Trop-2 expression in several, mostly epithelial, normal tissues (see breast, kidney and pancreas in Figures 3a and b) . The highest expression was found in differentiated layers of multistratified epithelia, 17 for example, skin, oesophagus and tonsils. Intermediate levels were found in lung, pancreas (exocrine glands only; endocrine islets are negative), prostate, salivary glands, urothelium and placental trophoblast, followed by liver (bile ducts). Occasional expression was found in endometrium and stomach. Heterogeneous reactivity was found in breast ductal epithelium and kidney cortex, with a subset of specialized cells with high levels of Trop-2 expression (Figure 3 ). No Trop-2 was detected in bone marrow, intestine, nervous system, ovary, pituitary gland, spleen, striated and cardiac muscle, adrenal gland and testis (Table 1, bottom;  Table 2 ; Supplementary Figure 1) .
The present findings (IHC, real-time PCR, SAGE and DNA microarray analyses) are at variance with claims of lack of expression of Trop-2 in most/all differentiated normal adult human tissues. 4, 6 Such claims appear also largely unsupported by previous work. 17 --19,21 More in detail, Fong et al. 9 showed expression of Trop-2 in the exocrine pancreas, while the islets of Langerhans were negative, in agreement with the present findings ( Figure 3 ; Table 2 ). Nakashima et al. 25 analysed normal oesophageal epithelium and detected Trop-2 by western blotting. Specific normal tissues have been shown not to express Trop-2 both by us and by others (that is, colon; 12,26 ovary; 14 and stomach 10 ) (Supplementary Figure 1 ; Table 1, bottom; Table 2 ). At variance with the present findings (Figure 3 , tonsil) and with previous L u n g K id n e y u t e r u s p a n c r e a s t e r m Trop-2 upregulation stimulates tumour growth M Trerotola et al evidence, 19, 20 Fong et al. 11 reported no staining of the normal oral mucosa. Differences in staining patterns might relate to differential Ab reactivities towards post-translationally modified molecule, as has been seen in other cases in tumour tissues, 27 or to heterogeneous expression of Trop-2 in different areas of the same tissue. Trop-2 Ab detection is, on the other hand, extremely sensitive to the staining conditions, 17 which makes extensive protocol optimization necessary to avoid artefactual lack of reactivity.
Of interest, the TROP2 mRNA expression patterns do not always match those of the Trop-2 protein. Major examples are endometrium and stomach, where TROP2 mRNA was detected in one third and two thirds of cases, respectively, whereas the Trop-2 protein was either infrequently detectable (endometrium) or essentially absent (stomach) ( Table 1) . Similarly, kidney demonstrated sizable mRNA levels, but overall undetectable Trop-2 protein, except for renal tubules cells (Figure 3 ). These findings are consistent with regulatory steps at the TROP2 mRNA translation and/or protein stability levels. Both such mechanisms have been confirmed. In SW480 colon cancer cells, degradation of TROP-2 mRNA was induced upon pharmacological treatment with epigallocatechin-3-gallate, a catechin with chemopreventive capacity. In HCT-116 cells, a parallel epigallocatechin-3-gallate treatment inhibited TROP-2 expression at a post-translational level. 28 Trop-2 expression increases in human tumours Trop-2 was found expressed in most tumours of epithelial origin (Figures 1c and d) , and its expression has been associated with tumour aggressiveness. 10 --13 As Trop-2 is also expressed in normal tissues, it was important to determine how Trop-2 expression in tumours compares with baseline levels. Comparative SAGE analyses showed upregulation of TROP2 in lung, breast, stomach, pancreas, liver, kidney, colorectal and ovarian cancers versus their corresponding normal tissues (Figure 2a ). Microarray analysis of TROP2 expression in breast cancer also showed overexpression in 83% of cases, as compared with normal breast tissue (Figure 2b ). These findings led us to perform stringent expression profiling of tumour versus normal tissues from individual patients. These matched cancer/normal tissue pairs (N ¼ 238) were analysed for expression of the TROP2 gene by filter hybridization. Upregulation of TROP2 mRNA was detected in essentially all tumour classes (breast, colon, lung, ovary, rectum and endometrium), versus their tissues of origin ( Figure 2c ; Table 1 , top), which is consistent with selective advantages for TROP2-mRNA-overexpressing tumour cells.
We then proceeded to analyse expression of the Trop-2 protein by IHC in a large tumour-versus-control set of samples (514 normal tissue samples and 1656 tumour tissue cases) ( Figure 5 ; for a subset of kidney cancers), as assessed by Fisher's exact test analysis of the normal tissue versus tumour tissue expression profiles. This cancer-related upregulation included tissues of origin that were low/nil for Trop-2 (colon, rectum, endometrium, kidney, ovary, and stomach), which suggests selective pressure for a switch-on of Trop-2 expression. Of note, however, breast, lung and prostate tissues do express Trop-2 under basal conditions. Nevertheless, Trop-2 was upregulated in their corresponding tumours, which indicates selective pressure for increased Trop-2 expression versus baseline levels.
Trop-2 is necessary and sufficient to stimulate transformed cell growth These findings led us to investigate whether upregulation of Trop-2 has a direct role in tumour cell growth ( Figure 6 ). A panel of immortalized (MTE 4-14 and NIH-3T3) and transformed (KM12SM and Igrov-1) cells that showed undetectable or low Trop-2 expression were transfected with a wild-type TROP2 gene under the control of a viral promoter ( Figure 6a ). Trop-2 overexpression markedly stimulated cell growth in all of these cell lines tested, in an invariant manner across histotypes (carcinoma and sarcoma) and species (human and murine) (Figure 6a ), both at early (MTE 4-14 and NIH-3T3 cells) and at late (KM12SM and Igrov-1) stages of transformation. As indicated above, KM12SM cells endogenously express low levels of TROP2, indicating that TROP2 upregulation is a driver of more rapid growth ( Figure 6a ). This growth-promoting effect was seen to correspondingly operate on experimental tumour growth in vivo (see below). More rapid growth rates of TROP2 transfectants were associated with higher proportions of the cells in S phase of the cell cycle ( Figure 6b ). Consistently, inhibition of TROP2 expression by small inhibitory RNA (siRNA) (Figure 6d ) significantly reduced growth rates of lowexpressing colon cancer cells (HCT-116 and KM12SM) and essentially abolished growth of the Trop-2 highly expressing MCF-7 mammary tumour cells (Figure 6e ). Hence, Trop-2 expression is both necessary and sufficient to stimulate tumour cell growth in vitro.
Trop-2 quantitatively stimulates tumour growth in vivo
We then assessed the role of Trop-2 in tumour growth in vivo (Figure 7 ). L cells homogeneously expressing discrete levels of wild-type Trop-2 were obtained from stable transfectants by flow cytometry cell sorting, 29, 30 with the highest expression corresponding to average expression levels of human cancer cells 3 ( Figure 7b ). L/TROP2 transfectants were injected subcutaneously in nude mice and tumour growth over time was assessed. Tumour growth rates were shown to be dramatically increased by Trop-2 overexpression (Figure 7a ), as were tumour take rates (manuscript in preparation). Similar findings were obtained with human 293 transfectants, which indicated a broad in-vivo relevance of Trop-2-driven cell growth stimulatory mechanics. Tumour growth was proportional to the expression levels of Trop-2 ( Figure 7a ). (Figures 7a and b) , indicating higher tumour aggressiveness. Consistently, histopathology analysis of these tumours shows a highly malignant phenotype, with increased mitotic activity, high nuclear pleomorphism, and giant multinucleated cells (Figure 7c) , which indicates that Trop-2 has a role in tumour progression. The growth stimulatory capacity of Trop-2 in MTE 4-14 and NIH-3T3 cells provided more evidence of a role for Trop-2 in tumour development, and suggested activity from early stages of cell transformation.
Hence, we assessed the role of Trop-2 in tumour progression in a human model. As indicated above, the colon mucosa does not express Trop-2. Consistent with a Trop-2-driven tumour progression model, a switch-on of Trop-2 expression was demonstrated in colon dysplastic mucosa, that is, at the earliest stages of cell transformation. Trop-2 expression levels further increased after neoplastic transformation ( Figure 5 ), thus supporting the role of Trop-2 as a driver of tumour progression.
Tumour growth is driven by overexpression of wild-type Trop-2 The findings above indicated that cancer growth is induced by overexpression of wild-type Trop-2. Together with previous evidence 31 and with the widespread expression of Trop-2 in normal tissues, this raised issues on a 'classical' oncogene role of Trop-2. 5 Baby rat kidney (BRK) primary cells and immortalized NIH-3T3 cells were thus assessed for transformation response to Trop-2 ( Figure 6c; Supplementary Figure 3a ; Table 3 ). Positive controls for cell transformation were mutated Harvey RAS (mutRAS) and the CYCLIN D1-TROP2 (CD1-T2) oncogenic chimera. 31 Vector-transfected BRK cells stopped growing and died after 3 --4 weeks in culture, and they did not generate foci. Only a few, short-lived foci were observed in experimental groups transfected with TROP2 and/or mutRAS. On the other hand, BRK cells transfected with oncogenic CD1-T2/mutRAS generated heavily confluent, multilayered immortal foci, which confirms and extends previous evidence 31 ( Figure 6c ; Table 3 , top). NIH-3T3 cells spontaneously generated foci over time in culture (wtRAS (wild-type Harvey RAS)-transfected cells). MutRAS increased this spontaneous transformation frequency, often leading to areas of multiple, heavily confluent foci, while TROP2-transfected cells generated the same number of foci as control wtRAS-transfected cells, but with a larger size (Figure 6c; Supplementary Figure 3a ; Table 3 , top). Hence, Trop-2 stimulates cell growth (Figures 6a and b) , but does not Trop-2 upregulation stimulates tumour growth M Trerotola et al detectably augment the focus-forming ability. TROP2-transfected NIH-3T3 cells were also assayed for their colony-formation ability in soft agar; again, there were no TROP2-specific transforming effects, although a trend was observed for a larger colony size in TROP2 transfectants (Table 3b ). Previous conflicting findings 5 are consistent with spontaneous cellular transformation in high serum cultures. 32 An additional bias is introduced by the higher take rates and growth velocity of TROP2-transfected cells in vivo (manuscript in preparation).
Oncogenes are often activated by structural alterations/point mutations. 33 Hence, we looked for structural alterations/point mutations of the TROP2 gene in different tumour types (Supplementary Figures 3b --d) . Full TROP2 gene sequences were obtained for 16 MEN-2A (multiple endocrine neoplasia type 2A) medullary thyroid cancers, 4 pheochromocytomas, 2 sporadic medullary thyroid cancers and 21 sporadic breast cancers. There was no evidence for cancer-related structural alterations/point mutations of TROP2. Only a polymorphic residue (Glu versus Asp) at position 216 was seen ( Supplementary Figures 2c and d) ; however, this E216D change did not appear to have a role in cell growth regulation (data not shown). Analysis of 44 additional tumour cases (http://www.sanger.ac.uk/genetics/CGP/cosmic/) extended the evidence on the absence of TROP2 mutations in tumours from breast (32 cases overall), colon (11 cases) and central nervous system (22 cases).
DISCUSSION
Trop-2 is a calcium signal transducer that has been associated with cancer aggressiveness, poor prognosis, 3,9,10,12 --14 and transformed cell growth in experimental systems. 4 --7,17,34 However, Trop-2 function in human cancer remained essentially unknown.
Here, we show by mRNA and protein expression profiling that Trop-2 is widely expressed in normal tissues. This is consistent with earlier evidence on the presence of Trop-2 in epidermis, 17 --20 exo-cervix, oesophagus, tongue, 19, 20 placental trophoblast 21 and urothelium. 20 Comparison of Trop-2 expression in tumours versus normal tissues showed that Trop-2 mRNA and protein are overexpressed by most cancers. This also occurs at sites where Trop-2 is natively expressed by normal cells, indicating that increased expression can confer a selective advantage to transformed cells.
Consistent with the above, we demonstrated that overexpression of the Trop-2 protein is necessary and sufficient for growth of human cancer cells, both in vitro and in vivo. Strikingly, Trop-2 expression was found to increase tumour growth irrespective of histotype (carcinoma and sarcoma) and species (human and murine), which indicates that Trop-2 is a conserved driver of tumour growth. Transcription factors have been recently identified that are major inducers of TROP2 expression, that is, P63, ERG, GRHL1, HNF1A, PU.1, WT1, FOXM1 and FOXP3. These were shown to conduct major cell growth control pathways, that is, NF-kB, cyclin D1, ERK/MEK, through TROP2 and HNF4A, thus starting shedding light on the mechanisms of TROP2 overexpression in tumours (submitted for publication). Selection for greater expression of an otherwise germ-line Trop-2 protein was shown to be sufficient to provide a critical growth advantage to the cancer cells. This appeared largely independent from direct transforming capacity and/or function-activatory structural alterations. 36 mTrop2 loss did not lead to detectable phenotypic changes, suggesting compensatory mechanisms for Trop-2 lossof-function, for example, through the paralogous molecule Trop-1/ Ep-CAM. 37 Of interest, Trop2 was found to have a tumourinhibitory role upon loss of Arf. The mechanisms of the Trop2/Arf interaction remain essentially unknown. However, the Trop2 antitumourigenic phenotype was only observed in sarcomatoid tumours, which had lost epithelial characteristics. Hence, re-introduction of Trop-2 may represent a 'revertant epithelial differentiation character', which may oppose epithelial-tomesenchymal transition-related malignant progression. Moreover, Trop-2 is widely expressed by normal tissues and only overexpression is pro-tumourigenic. Hence, partial restoration of inadequately processed Trop-2 protein 36 was most likely inadequate to demonstrate a pro-tumourigenic role.
Thus, taken together, our findings support a scenario where the tumour growth-promoting role of Trop-2 is distinct from that of classical, cell-transforming oncogenes. This concept has recently gained momentum as a 'non-oncogene addiction' model. 35 One of the best-described systems so far is that of heat-shock transcription factor 1 (HSF1).
36 HSF1 stimulates tumour growth by inducing the formation of the complex HSP90-Cdc37, which counteracts the inactivation of various key regulators of cell proliferation and survival, such as the Cdk4, HER2/ErbB2 and Akt kinases. No somatic mutations in HSF1 have been identified in human cancers. Moreover, unlike mutant Ras, overexpression of HSF1 did not transform immortalized mouse embryonic fibroblasts. Embryonic fibroblasts lacking HSF1 were refractory to transformation induced by either mutRAS or PDGF-B, 38 supporting the concept that growth-promoting genes have distinct functional properties from bona fide oncogenes.
Our findings candidate Trop-2 to be a novel player in processes of non-oncogene addiction of cancer cells. Knowledge on Trop-2 distribution, function and regulated expression may help 
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Mucoid cancer Mucoid cancer Adenocarcinoma Adenocarcinoma Figure 5 . Trop-2 protein expression in tumour progression. Representative IHC analysis of Trop-2 expression at different stages of colon tumour progression, from normal to fully neoplastic. Normal colon mucosa shows no detectable Trop-2 expression; dysplastic colon mucosa shows induction of Trop-2 expression, higher levels being observed towards the lumen of the glands; colon cancers (mucoid, adenocarcinoma) show higher levels of Trop-2 expression than dysplastic cells.
Trop-2 upregulation stimulates tumour growth M Trerotola et al kidney 293 cells were grown in RPMI-1640 medium, 10% fetal bovine serum (GibcoBRL, Paisley, Scotland). Murine MTE 4-14, 39 NIH-3T3 and L cells, 40 and BRK cells 31 were maintained in DMEM 10% fetal bovine serum.
In-vitro cell growth assays
Cells transfected with the human TROP2 gene or siRNAs were seeded at 2 Â 10 3 cells/well in 96-well plates (five replica wells per data point). Cell numbers were quantified by staining with crystal violet (Sigma, St Louis, MO, USA). 41 Cell growth curves were normalized against a standard reference curve (Crystal violet absorbance of twofold serially diluted cell samples). Cells were also quantified with the MTT colorimetric assay (Roche Diagnostics Deutschland GmbH, Mannheim, Germany) following manufacturer's instructions.
Cell-cycle analysis MTE 4-14 TROP2 and control transfectants were stained with 45 mg/ml propidium iodide (Calbiochem, Gibbstown, NJ, USA) for 60 min, and analysed for cell-cycle phase distribution, essentially as described previously. 42 
Plasmids and DNA transfection
The pBJI-neo vector (HTLV-1 promoter) was provided by M Davis. The pDEYFP vector (CMV promoter) was derived from pEYFP-N1 (Clontech, Palo Alto, CA, USA) by removal of the EYFP coding sequence. Both vectors were used to express human TROP2 (X77753) with essentially identical results. The plasmids pUHD15-1 (tetracycline transactivator) and pUHC13-3 (tetracycline-responsive promoter) for tetracycline-inducible gene expression were kindly provided by Dr Bujard. 43 The ponasterone-inducible pIND vector 44 was provided by Dr Wolter. 45 DNA transfection 46 was performed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
Inducible TROP2 expression
A Drosophila melanogaster ecdysone-inducible expression vector (pIND-TROP2) was assembled as described. 45 The 293 cell transfectants for the pIND-TROP2 were obtained and Trop-2 expression was induced by incubation with 2 mM of the ecdysone analogue ponasterone A for the times indicated. 45 The pUHC13-3-TROP2 tetracycline-inducible expression construct was constructed and used as described. 43 L-cell transfectants for the pUHD-TROP2 were obtained and injected subcutaneously in nude (Table 3a) . Bottom right: wtRAS does not increase spontaneous in-vitro transformation rates (Table 3a) . Magnification: Â 20. (d) TROP2 mRNA knockdown using siRNA oligonucleotides, assessed by quantitative real-time RT --PCR. TROP2 mRNA levels in HCT-116 cells transfected with the empty (control) or indicated vectors were measured as DC T (C T, TROP2 -C T, GAPDH ) and 1.834 ÀDDCT scores 31 (see Materials and methods). All samples were assayed in triplicate, with mean±s.e.m. shown. (e) Representative growth curves of control, empty vector or irrelevant siRNA and siRNA transfectants of TROP2-expressing cell lines. Silencing endogenous TROP2 expression inhibits cell growth in vitro. Mean ± s.e.m. is shown. Several TROP2-targeting siRNAs (#5, #13, #19, #20) efficiently reduced TROP2 mRNA levels and had similar inhibitory effects on growth. For convenience, siRNA#19 was used on additional cell lines.
Trop-2 upregulation stimulates tumour growth M Trerotola et al mice. Trop-2 expression was induced by continuous administration of 2 mg/ml doxycycline in drinking water. 47 Small-inhibitory (si)RNA TROP2-targeting siRNAs were designed following: Tuschl' criteria (#4, #5, #10, #12, #18), that is, position in mRNA, GC content, base composition and flanking sequences; 48 Invitrogen algorithms (#19 and #20) (rnaidesigner. invitrogen.com/rnaiexpress/), that is, sequence composition, thermodynamic properties and comparison with validated siRNAs; Sonnhammer procedure (#13, #19 and #20) (sonnhammer.cgb.ki.se/siSearch/), that is, siSearch on data banks of validated siRNAs, motif rules and thermodynamic parameters. 49 
Antibodies
The 162-46.2 (ATCC clone HB187) and T16 anti-Trop-2 mAb 17, 40 were used for IHC and flow cytometry or confocal microscopy, respectively. Cellsurface Trop-2 in IHC was revealed with the AF650 goat anti-Trop-2 pAb (R&D Systems).
Flow cytometry immunofluorescence and cell sorting Enrichment for expressing transfectants was performed by magnetic cell sorting (MACS; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Cell staining, fluorescence analyses and sorting (FACScalibur, FACScan, Becton Dickinson, Sunnyvale, CA, USA) were performed as described. 51 
DNA microarray analysis
The DNA microarray data from normal human tissues were analysed as previously described 52 (http://www.ncbi.nlm.nih.gov/projects/geo/). Median expression levels were used as the threshold to identify tissues expressing TROP2.
Quantitative RT --PCR analysis RNA was extracted in Trizol (Invitrogen). In all, 1 mg total RNA was reverse transcribed (ImProm-II Reverse Transcriptase; Promega, Madison, WI, USA). The cDNA was quantified by ethidium bromide fluorescence in solution. 53 Quantitative RT --PCR was performed using an ABI-PRISM 7900HT (Applied Biosystems, Foster City, CA, USA) and TaqMan (Roche) probes and primers (TROP2: Hs00242741; GAPDH: Hs99999905), according to the manufacturer instructions. 31 Each sample was assayed in triplicate and the 1.834
ÀDDCT method 31 was used to calculate the relative changes in gene expression. mRNA profiling-DNA macroarray analysis Expression of TROP2 in human tumours was assessed by dot-blot analysis of cDNA profiling arrays (Clontech), using a TROP2 PCR fragment labelled with [a-32 P]-dATP. cDNA from nine cancer cell lines was used as the hybridization and expression controls. Equal loading of the different cDNAs was verified using a human ubiquitin probe.
Expressed sequence tag (EST) analysis
TROP2 EST abundance in shotgun-sequenced libraries was quantified as described (http://www.ncbi.nlm.nih.gov/UniGene/). Data were displayed with UniGene EST ProfileViewer.
Serial analysis of gene expression SAGE analysis of TROP2 expression was conducted as described (cgap.nci.nih.gov/SAGE/). Short sequences (10 --14 bp) from the 3 0 region of TROP2 mRNA were used as unique identification tags; quantitative expression data were obtained from sequenced tag concatamers, and displayed as SAGE Anatomic Views.
Focus-formation assay BRK primary cells were transfected with 10 mg carrier genomic DNA and 10 mg Trop-2-expressing plasmids co-precipitated in calcium phosphate; 31 NIH-3T3 cells were transfected with 2 mg expression constructs by lipofection. Oncogenic CD1-T2 chimera, mutRAS and normal Ha-RAS (wtRAS) were used as controls for cell transformation. 51 Transfected BRK and NIH-3T3 cells were seeded at 10 6 cells/10 cm diameter plates and allowed to grow to confluence, changing medium twice a week. Foci were counted 4 weeks after seeding.
Soft-agar colony-formation assay NIH-3T3 transfectants (vector alone versus TROP2) (2Â 10 4 cells) were resuspended in DMEM plus 10% fetal bovine serum, 0.4% agarose. Cells were then seeded onto a 0.5% agar base that was supplemented with DMEM plus 10% fetal bovine serum, as triplicate samples in six-well plates, changing medium twice a week. Colonies were counted 30 days after seeding.
Immunohistochemistry
Sample tissue microarrays were prepared as described. 54 Tissue microarrays were also obtained from Oridis (Graz, Austria) (http://www. oridis-biomed.com/). In all, 5-mm sections were mounted on silanized slides, deparaffinized and rehydrated. Endogenous peroxidase was blocked with 3% H 2 O 2 for 5 min. Slides were treated with 0.3% BSA/Tris, to quench non-specific binding, and incubated at room temperature for 30 min with the relevant Abs. Cell-surface Trop-2 was revealed using a goat anti-Trop-2 pAb (AF650; R&D Systems), 1:25 dilution, 40 min room temperature. Bound antibodies were detected with goat anti-rabbit or anti-mouse horseradish peroxidase-labelled polymerized pAb (DAKO EnVision TM System; Dako, Glostrup, Denmark). Goat anti-Trop-2 antibodies were revealed with signal-amplification LSAB kit (K0679; Dako). Peroxidase activity was visualized with diaminobenzidine (Dako). Slides were counterstained with Mayer's haematoxylin. In control sections, the primary Abs were replaced with non-immune serum or isotype-matched immunoglobulins (Dako). Slides were independently scored by two pathologists (MP and RL).
Immunoelectron microscopy
Immunogold EM analysis was performed as described. 55 Cells were fixed in 4% formaldehyde, 0.05% glutaraldehyde, 0.15 M HEPES, pH 7.3, for 10 min at 37 1C, and post-fixed for 50 min in 4% paraformaldehyde, 0.15 M HEPES, pH 7.3 at room temperature. Cationized gold, protein A-gold, and antirabbit gold antibodies (10 nm colloidal gold particles) were from British BioCell (Cardiff, UK). Immunoperoxidase EM analysis was performed according to Brown and Farquhar. 56 Cells were fixed in 4% formaldehyde, 0.05% glutaraldehyde, 0.15 M HEPES, pH 7.3, and processed as described. 56 Figure 3a) ; confluent foci were counted as a unit.
d CD1-T2 oncogenic chimera. No statistically significant differences between subgroups were detected as assessed by t test, except for a trend for larger colony size for TROP2 transfectants (P ¼ 0.07).
